Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
10.73
+1.21 (12.71%)
At close: Jun 26, 2026, 4:00 PM EDT
10.90
+0.17 (1.58%)
After-hours: Jun 26, 2026, 7:53 PM EDT
Akari Therapeutics, Employees
As of December 31, 2025, Akari Therapeutics, had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 3 or -33.33% compared to the previous year.
Employees
6
Change (1Y)
-3
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,674,667
Market Cap
12.28M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | -3 | -33.33% | 5 | 1 |
| Dec 31, 2024 | 9 | -3 | -25.00% | 8 | 1 |
| Dec 31, 2023 | 12 | -3 | -20.00% | 9 | 3 |
| Dec 31, 2022 | 15 | 6 | 66.67% | 15 | 0 |
| Dec 31, 2021 | 9 | 0 | - | 9 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| OSR Health | 22 |
| SeaStar Medical Holding | 17 |
| Theriva Biologics | 16 |
| BioRestorative Therapies | 14 |
| Kiora Pharmaceuticals | 13 |
| Psyence Biomedical | 12 |
| Intensity Therapeutics | 7 |
AKTX News
- 1 day ago - Akari Therapeutics, Registration statement: Registration filing - Filings
- 23 days ago - Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026 - GlobeNewsWire
- 23 days ago - Akari Therapeutics, Proxy statement: Proxy filing - Filings
- 4 weeks ago - Akari Therapeutics trading resumes - TheFly
- 4 weeks ago - Akari Therapeutics trading halted, volatility trading pause - TheFly
- 4 weeks ago - Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance - GlobeNewsWire
- 4 weeks ago - Akari Therapeutics trading halted, volatility trading pause - TheFly
- 4 weeks ago - Akari Therapeutics trading resumes - TheFly